Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.…
Oncology Clinical Trials - Global Strategic Business Report 2026: Secure Share of a $6 Billion Revenue Surge by 2032 as AbbVie, AstraZeneca, ICON, Merck, and Roche Accelerate AI-Led Trials
Roche Holding (SWX: ROP) is listed on the SIX Swiss Exchange, where its shares trade in CHF. It belongs to the Drug Manufacturers - General industry, part of the Healthcare sector.
The shares were at 396.50 CHF on 20 November 2026, up 33.3% over 52 weeks. Its 52-week range is 291.00 CHF to 410.90 CHF: the price is 3.5% below the high and 36.3% above the low.
At a market capitalisation of 316.16B CHF, it trades at 25.9 times trailing earnings and 18.0 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - General peers is 25.3, so ROP is valued in line with them. It pays a dividend yielding 2.45% (it pays out 64% of its earnings), against a median of 2.78% among the dividend payers in that peer group.
Roche Holding reports return on equity of 38.1%, an operating margin of 33.1% and revenue down 1.2% year over year.
Its debt exceeds its cash by 23.57B CHF, a debt-to-equity ratio of 0.98. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health. 21 analysts cover the stock, with an average rating of Buy; their mean price target of 397.79 CHF is 0.3% above the current price. The next earnings report is expected on 28 January 2027.